Advances in Immunology - 1st Edition - ISBN: 9780128047989, 9780128052143

Advances in Immunology, Volume 131

1st Edition

Serial Editors: Frederick Alt
eBook ISBN: 9780128052143
Hardcover ISBN: 9780128047989
Imprint: Academic Press
Published Date: 26th May 2016
Page Count: 262
Tax/VAT will be calculated at check-out Price includes VAT (GST)
30% off
30% off
30% off
30% off
30% off
20% off
20% off
30% off
30% off
30% off
30% off
30% off
20% off
20% off
30% off
30% off
30% off
30% off
30% off
20% off
20% off
138.00
96.60
96.60
96.60
96.60
96.60
110.40
110.40
117.00
81.90
81.90
81.90
81.90
81.90
93.60
93.60
193.00
135.10
135.10
135.10
135.10
135.10
154.40
154.40
Unavailable
Price includes VAT (GST)
× DRM-Free

Easy - Download and start reading immediately. There’s no activation process to access eBooks; all eBooks are fully searchable, and enabled for copying, pasting, and printing.

Flexible - Read on multiple operating systems and devices. Easily read eBooks on smart phones, computers, or any eBook readers, including Kindle.

Open - Buy once, receive and download all available eBook formats, including PDF, EPUB, and Mobi (for Kindle).

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

  • Chapter One: Malondialdehyde Epitopes as Targets of Immunity and the Implications for Atherosclerosis
    • Abstract
    • 1 Overview
    • 2 Biochemistry and Generation of MDA In Vitro and In Vivo
    • 3 Generation of MDA Epitopes
    • 4 Carriers of MDA Epitopes
    • 5 Targets of Immune Response
    • 6 Innate Immune Responses Toward OSEs
    • 7 Adaptive Immunity Responses on MDA Epitopes
    • 8 MDA Epitopes in Diseases
    • 9 Relevance of OSEs in Cardiovascular Disease
    • 10 MDA Epitopes in Atherosclerosis
    • 11 MDA Epitopes as Therapeutic Targets in Cardiovascular Disease
    • 12 Conclusions
  • Chapter Two: Factors That Regulate the Generation of Antibody-Secreting Plasma Cells
    • Abstract
    • 1 Germinal Center
    • 2 Plasma Cells
    • 3 Memory B Cells
    • 4 Blimp-1 Is a Key Regulator of Plasma-Cell Differentiation
    • 5 Perspectives
    • Acknowledgments
  • Chapter Three: Deep Profiling Human T Cell Heterogeneity by Mass Cytometry
    • Abstract
    • 1 Introduction
    • 2 T Cell Heterogeneity: Days of Future Past
    • 3 Mass Cytometry: Experimental Workflow and Data Processing
    • 4 Mass Cytometry: Panel Design for T Cell Analysis
    • 5 Probing T Cell Specificity: From Single to Multiplex Tetramer
    • 6 Dissecting Mass Cytometry Data: High-Dimensional Data Analysis
    • 7 Future Perspectives
    • 8 Concluding Remarks
    • Acknowledgments
  • Chapter Four: Germinal Center B-Cell-Associated Nuclear Protein (GANP) Involved in RNA Metabolism for B Cell Maturation
    • Abstract
    • 1 Introduction
    • 2 Affinity Maturation and Ab Specificity
    • 3 Molecules Associated with Ab Affinity Maturation
    • 4 Germinal Center B-Cell-Associated Nuclear Protein
    • 5 Structure of GANP
    • 6 GANP-Associated Proteins
    • 7 Transcription-Coupled IgV Region SHM
    • 8 TREX-2 and Diseases
    • 9 Perspectives
    • Acknowledgments
  • Chapter Five: Advances in PET Detection of the Antitumor T Cell Response
    • Abstract
    • 1 Introduction
    • 2 Ex Vivo Cell Labeling for Tracking Immune Cells In Vivo
    • 3 Small Molecule Metabolite Probes for Tracking T Cells
    • 4 PET Reporter Imaging for Tracking Engineered Cells In Vivo
    • 5 In Vivo Detection of Immune Cells Using Radiolabeled Proteins
    • 6 Concluding Remarks and Future Direction of PET Imaging the Antitumor T Cell Response
    • Acknowledgments
  • Index
  • Contents of Recent Volumes

Description

Advances in Immunology, a long-established and highly respected publication, presents current developments as well as comprehensive reviews in immunology. Articles address the wide range of topics that comprise immunology, including molecular and cellular activation mechanisms, phylogeny and molecular evolution, and clinical modalities. Edited and authored by the foremost scientists in the field, each volume provides up-to-date information and directions for the future.

Key Features

  • Contains contributions from leading authorities
  • Includes a wide range of topics that comprise immunology, including molecular and cellular activation mechanisms, phylogeny and molecular evolution, and clinical modalities
  • Informs and updates on all the latest developments in the field of immunology

Readership

Immunologists and infectious disease specialists, cell biologists and hematologists.


Details

No. of pages:
262
Copyright:
© Academic Press 2016
Published:
Imprint:
Academic Press
eBook ISBN:
9780128052143
Hardcover ISBN:
9780128047989

About the Serial Editors

Frederick Alt Serial Editor

Frederick Alt received his Ph.D. in Biology from Stanford University in 1977 where he worked with Robert Schimke and discovered gene amplification and genomic instability in mammalian cancer cells. Alt moved to MIT for postdoctoral work with David Baltimore, where he helped elucidate basic principles of recombination in the immune system. His work with Baltimore included the discovery that production of membrane versus secreted immunoglobulin is achieved via differential RNA processing and the discovery that allelic exclusion of Immunoglobulin (Ig) gene rearrangements is controlled by feedback from protein products. With Baltimore, Alt also elucidated major aspects of the V(D)J recombination mechanism, including involvement of site-specific DNA double strand breaks (DSBs) that are end joined, and the discovery of ”N” regions, which represent a major source of antigen receptor diversity.

Dr. Alt moved to Columbia University in 1982 as Assistant Professor of Biochemistry. He became Professor of Biochemistry and Molecular Biophysics in 1985 and HHMI Investigator in 1987. At Columbia, he established the role of Ig chains in regulating B cell development and discovered that antigen receptor genes are assembled by a common V(D)J recombinase. He then elucidated a role for non-coding gene transcription and "chromatin accessibility" as means to target the lineage, stage, and allele specific activity of the V(D)J recombinase. He extended that work to show that IgH class switch recombination (CSR) is B cells to particular IgH classes is directed by activation of non-coding transcription units that contain the CSR target sequences. At Columbia, he also discovered N-myc, based on its amplification in human neuroblastomas and he characterized the Myc cellular oncogene family.

In 1991, Dr. Alt moved to Boston Children' Hospital (BCH) and Harvard Medical School as a Professor of Genetics and HHMI Investigator. He also became a Senior Investigator at the Immune Disease Institute (IDI). He was appointed Charles A. Janeway Professor of Pediatrics in 1993, Scientific Director of IDI in 2005, and Director of the Program in Cellular and Molecular Medicine (PCMM) at Children's Hospital in 2008. He also became President of IDI in 2010 and continues to serve as director since the merger of IDI with BCH where it remains the PCMM. At CHB and IDI, Dr. Alt's group confirmed his earlier proposal with Baltimore that N regions are added by terminal dexoynucleotidyl transferase, demonstrating that TdT is a V(D)J recombinase component. They also discovered that the joining activity of the V(D)J recombinase is carried out by a multi-component general cellular non-homologous DNA end joining (NHEJ) pathway. Subsequently, Dr. Alt was involved in the discovery of a number of the NHEJ factors and he then went on to discover the key role of NHEJ proteins in maintenance of genomic stability. Dr. Alt continues to elucidate many new aspects of the mechanism and control of V(D)J recombination and IgH CSR and also continues to elucidate mechanisms that generate and suppress genomic instability, most recently through development of high through-put methods to study DSBs and chromosomal translocations.

In 1994, Dr. Alt was elected to the U.S. National Academy of Sciences, the American Academy of Arts and Sciences, and the American Academy of Microbiology; in 1999 he was elected to the European Molecular Biology Organization; in 2010 he was elected a Fellow of the American Association for Advancement of Sciences; and in 2011 he was elected to the Institute of Medicine. In 2004, Alt received the Clowes Memorial Award from AACR; in 2005 he received the Rabbi Shai Shacknai Prize from Hebrew University, the Pasarow Foundation Prize for Extraordinary Achievement in Cancer Research, the Leukemia & Lymphoma Society de Villiers International Achievement Award, and the Irvington Institute Award. In 2007, Alt received the NCI Alfred K. Knudson Award for pioneering contributions that have revolutionized Cancer Genetics, the AAI-Huang Meritorious Career Award, and the Novartis Basic Immunology Prize for his discoveries on B cell development and antigen responses. In 2009, he received the Cancer Research Institute William B. Coley Award for Distinguished Research in Basic Immunology for fundamental contributions to understanding of B-cell development and B cell lymphomagenesis. For his overall contributions, he most recently received the 2012 Arthur Kornberg and Paul Berg Award for Lifetime Achievement in Biomedical Sciences from Stanford University Medical School. Dr. Alt serves on numerous editorial boards and is Editor in Chief of Advances in Immunology. He also has served on various national and international advisory boards and is currently Chair, of the SAC of the Cold Spring Harbor Laboratory. Dr. Alt has mentored over 100 students and research fellows, many of whom have become leaders in immunology, genetics, or cancer biology and he received the 2003 American Association of Immunologists Excellence in Mentoring Award. The Cancer Research Institute of New York annually presents the Frederick W. Alt Award for New Discoveries in Immunology.

Affiliations and Expertise

Harvard Medical School, Boston, MA, USA